Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03579472 · ClinicalTrials.gov registry record · Phase 1
M7824 and Eribulin Mesylate in Treating Patients With Metastatic Triple Negative Breast Cancer
A Phase 1 study, sponsored by M.D. Anderson Cancer Center.
- Terminated
- Registry status
- Phase 1
- Development phase
- 38
- Enrollment target
NCT03579472: Clinical Trial Phase 1 study, sponsored by M.D. Anderson Cancer Center.
NCT03579472 is a Phase 1 study that was terminated before completion, run by M.D. Anderson Cancer Center. The registered enrollment target is 38 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03579472, a Phase 1 study, was terminated before completion, sponsored by M.D. Anderson Cancer Center.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 38 participants
- Enrollment target
Study Summary
This phase Ib trial studies the best dose and side effects of eribulin mesylate when given together with M7824)in treating patients with triple negative breast cancer that has spread to other places in the body. Drugs used in chemotherapy, such as eribulin mesylate, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Immunotherapy with monoclonal antibodies, such as M7824, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving eribulin mesylate and M7824 may work better at treating triple negative breast cancer.
Interventions
- DRUG Bintrafusp Alfa
- DRUG Eribulin Mesylate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 38 participants |
| Start Date | 2018-05-30 |
| Est. Completion | 2022-09-21 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03579472
The ClinicalTrials.gov registry entry for NCT03579472 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 38 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Bintrafusp Alfa is the first listed.
NCT03579472 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03579472 about?
NCT03579472 is a clinical study titled "M7824 and Eribulin Mesylate in Treating Patients With Metastatic Triple Negative Breast Cancer". This phase Ib trial studies the best dose and side effects of eribulin mesylate when given together with M7824)in treating patients with triple negative breast cancer that has spread to other places in the body. Drugs used in chemotherapy, such as eribulin mesylate, work in different ways to stop th...
What is the current status of trial NCT03579472?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 38 participants. The study started on 2018-05-30. Estimated completion is 2022-09-21.
What interventions are being tested in trial NCT03579472?
The interventions under investigation include: Bintrafusp Alfa (DRUG), Eribulin Mesylate (DRUG).
Who is sponsoring clinical trial NCT03579472?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.